A 45-day longitudinal study tracked daily anxiety relief in 416 medical cannabis patients. Cannabis-use days showed larger same-day reductions, but the design limits causal conclusions. Here’s what the data support, and what they don’t.
ARTELO BIOSCIENCES, INC. SEC 10-K Report – TradingView
WHY IT MATTERS: If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does. CLINICAL OVERVIEW: Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids.
Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
WHY IT MATTERS: If you are pregnant or planning to become pregnant and currently use cannabis, this research underscores why having an honest, judgment-free conversation with your physician about timing, risks, and alternatives is essential for both your care and your baby’s long-term neurodevelopmental health. CLINICAL OVERVIEW: Emerging research is exploring how prenatal cannabis exposure may alter genetic markers in the placenta, particularly in pregnancies associated with low birth weight, and whether those placental changes could serve as early indicators of neurodevelopmental risk including schizophrenia. This builds on what we already know clinically about the endocannabinoid system’s critical role in fetal brain development and placental function.
America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education …
WHY IT MATTERS: When media and policymakers frame cannabis use as a “problem” rather than an education gap, it slows the development of clinical programs, physician training, and insurance coverage that patients need to access safe, guided care. CLINICAL OVERVIEW: The framing of cannabis as a “marijuana problem” in mainstream media reflects a deeper failure in clinical education, research access, and regulatory coherence rather than an inherent danger of the plant itself. Physicians are not trained in endocannabinoid medicine during medical school, research remains federally restricted, and patients are left navigating a fragmented system without proper clinical guidance.
Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
WHY IT MATTERS: If you are a parent or caregiver of a teen, or a young person using cannabis yourself, this research reinforces that delaying use until the brain is more fully developed, typically into the mid-20s, is one of the most important harm reduction strategies available. CLINICAL OVERVIEW: Emerging research continues to reinforce what clinicians have observed for years: adolescent cannabis use, particularly during critical neurodevelopmental windows, is associated with a meaningful increase in risk for serious psychiatric conditions including psychotic and bipolar disorders. The developing brain remains uniquely vulnerable to exogenous cannabinoids, and the endocannabinoid system plays a central role in synaptic pruning and neural circuit maturation during the teenage years.
Boulder and CBD: The Entourage Effect Explained | About Boulder County Colorado
WHY IT MATTERS: If you are currently using a CBD isolate product and not experiencing the relief you expected, the entourage effect suggests that switching to a full-spectrum formulation containing multiple cannabinoids and terpenes may provide meaningfully better results. CLINICAL OVERVIEW: The entourage effect describes how the full spectrum of cannabinoids, terpenes, and flavonoids in the cannabis plant work synergistically to produce therapeutic outcomes that isolated compounds alone cannot replicate. In clinical practice, patients using whole-plant or full-spectrum formulations frequently report more robust and nuanced symptom relief compared to those using single-molecule isolates like pure CBD or pure THC.
Munchies phenomenon: WSU study looks into benefits of cannabis use and hunger – KIRO 7
️ The science behind the munchies is more important than you think. New research from WSU is exploring how THC activates cannabinoid receptors in the brain to stimulate appetite, even when the body isn’t hungry. Here’s why this matters clinically: Patients with cancer, HIV, and chronic illness often struggle with dangerous appetite loss Understanding the endocannabinoid system helps us dose more precisely ️ Not everyone wants appetite stimulation, so knowing the mechanism helps us manage side effects too This research bridges the gap between patient experience and clinical evidence Better science = better care at the bedside The “munchies” aren’t just a punchline. For many patients, appetite stimulation is the reason they turned to cannabis in the first place. Drop a if cannabis has helped you or someone you know with appetite issues. New WSU research explains how THC triggers appetite at the brain level, validating what cannabis patients have known for years. Better science means better dosing.
Full-Spectrum Cannabis Extract Shows Significant Pain Reduction in Chronic Neuropathic Pain
If you live with chronic nerve pain, this study provides clinical evidence that full-spectrum cannabis extracts can deliver meaningful relief with fewer side effects than many conventional pain medications. A clinical study found that a full-spectrum cannabis extract containing a balanced ratio of THC and CBD produced statistically significant reductions in chronic neuropathic pain compared to placebo. Patients reported meaningful improvements in pain intensity, sleep quality, and overall quality of life with minimal adverse effects.
Satiety Bypass: How Cannabis Overrides the Brain’s ‘I’m Full’ Signal
A massive study tracking over 460,000 teens found that cannabis use during adolescence doubled the risk of psychotic and bipolar disorders, underscoring why age restrictions and youth prevention are critical. Neuroscience News deep-dive into the WSU/Calgary PNAS study on cannabis-induced appetite. THC activates CB1 receptors in the hypothalamus to override natural satiety signals, creating a feeling of starvation even in recently fed subjects.
Cannabis: What Is the Profile of Adults at Low Risk of Dependence?
Scientists have mapped exactly how THC tricks your brain into feeling starving even when you’re full, which opens the door to developing appetite-boosting medications without the psychoactive high. A University of Montreal study published in the Journal of Cannabis Research found that among Quebec adults in their mid-30s who used cannabis in the past year, 63% were at low risk for cannabis use disorder (CUD). Lower-risk users tended to use cannabis occasionally and in social contexts, and were more likely to be women or to co-use cannabis with alcohol rather than tobacco.